Chemomab Therapeutics Ltd.
CMMB- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001534248
In the last 90 days, Chemomab Therapeutics Ltd. insiders filed 0 open-market purchases and 1 sale; 13 institutions reported holding it in 13F filings for Q2 2026, worth $615.3K in total; no superinvestor holds it.
Q3 2025 vs. Q2 2025
How the institutions holding Chemomab Therapeutics Ltd. changed between Q2 2025 and Q3 2025.
All holders in Q3 2025All holders in Q2 2025
| Measure | Q2 2025 | Q3 2025 | Change |
|---|---|---|---|
| Holders | 14 | 10 | −4 |
| SharesConverted for a 1-for-4 split | 1.06M | 390.3K | −667.4K (−63.1%) |
| Value | $4.91M | $1.03M | −$3.88M (−79.1%) |
New holders (1)
Institutions that held Chemomab Therapeutics Ltd. at the end of Q3 2025 but not at the end of Q2 2025.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Stonepine Capital Management, LLC | 30,000 | $78.9K | 0.06% |
Sold out (5)
Institutions that held Chemomab Therapeutics Ltd. at the end of Q2 2025 and filed for Q3 2025 without it.
| Institution | Shares, Q2 2025 | Value, Q2 2025 |
|---|---|---|
| OrbiMed Advisors LLC | 940,990 | $1.09M |
| Yelin Lapidot Holdings Management Ltd. | 578,291 | $670.8K |
| Kestra Private Wealth Services, LLC | 31,241 | $36.2K |
| Boothbay Fund Management, LLC | 26,189 | $30.4K |
| JPMorgan Chase & Co | 1,180 | $1.37K |